← Russell 3000 cross-section

NEO NEOGENOMICS INC

Trailing twelve months to 2026-06-30 · as filed 2026-07-28, not restated
Healthcare

Scale

Market cap
$2.5bn
Revenue TTM
$766m
Net income TTM
$-52m
Free cash flow
$-7m
Composite score
41.8
Sector rank
#1510

Valuation

P / E
EV / EBITDA
EV / sales
3.5
FCF yield
-0.30%
Earnings yield vs 10-yr
-6.82pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-6.8%
EBITDA margin
-0.4%
ROE
-6.6%
ROIC
-6.8%
Revenue growth
11.2%

Insider activity, last 90 days

Net open-market
$-0.44m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our Community Channel Strength • Continue purposeful expansion into the community oncology market, leveraging the strategic position that we've established with community hospitals; • Expand adoption of our broader testing portfolio through increased commercial reach and frequency, including targeted investments in sales and commercial resources; and • Deliberately leverage partnerships to expand our market presence and accelerate our topline growth. Our sales team is focused on value-based care solutions and end-to-end client experience as a growth driver. …NEOGENOMICS INC, 10-Q, period ended 2026-06-30, filed 2026-07-28

Read the full passage →